Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on patients with Coronary artery disease who need a type of heart operation called off-pump coronary artery bypass surgery. To help reduce bleeding during and after the operation, the medication tranexamic acid is being given either as a pill taken by mouth (oral) or as a medicine given through a vein (intravenous).
The main goal is to see whether the pill form works at least as well as the vein form in lowering the amount of blood that drains from the chest in the first day after surgery. Participants will receive the assigned form of the drug before the operation and will be monitored for blood loss, need for blood transfusion, and other safety checks during the hospital stay.
After the surgery, the amount of fluid collected from chest tubes will be measured for 24 hours, and patients will stay in the intensive care unit and then the regular hospital ward while doctors watch for any complications such as kidney problems or clotting events. The study will follow each participant for about a month after the operation to record any further issues.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
4 criteria
9 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medicine taken by mouth in tablet form. In this study it is the test treatment. The tablets are designed to be swallowed before or during surgery to help the blood clot more quickly, which can reduce the amount of bleeding after the heart operation. By giving the drug this way, researchers want to see if it works as well as the injection form in keeping blood loss low.
is the same medicine but given through a needle into a vein. In the trial it serves as the comparator treatment. The injection is administered during the coronary artery bypass surgery to help the blood clot and limit bleeding from the surgical site. The study compares this standard method with the oral tablets to find out if the tablets are just as effective at preventing blood loss.
This medication comes as a film‑coated tablet that is taken by mouth. It is an approved drug that is widely used and described in medical literature for preventing excess bleeding. It is mainly used to reduce blood loss during surgery, trauma, and heavy menstrual bleeding. It works by blocking the enzyme that breaks down blood clots, and it belongs to the antifibrinolytic class of medicines.
This product is a clear solution for injection that is given directly into a vein. It is a well‑established, approved drug with extensive evidence in clinical studies for controlling bleeding. It is used to limit blood loss in surgeries, trauma, and other situations where bleeding is a risk. It prevents clot breakdown by inhibiting plasmin formation and is classified as an antifibrinolytic agent.
Other trials in this disease – keep exploring while you decide
Finland
Poland
Belgium
Denmark
SpainDenmarksourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
